Incyte Corporation, a company specializing in the development of therapeutic products for cancer and inflammatory diseases, has been given a neutral rating by UBS.

The majority of Incyte's revenue comes from product sales, which make up 85.6% of net sales. In addition to product sales, Incyte also earns revenue from license income, which contributes 14.2% to its overall revenue. Income from research and collaboration agreements is a small portion of Incyte's revenue, accounting for only 0.2%. This breakdown of revenue emphasizes Incyte's strong focus on product sales as its primary source of income.